Phaseline

Companies › General Oncology

General Oncology: clinical trials, targets and expected readouts

3 active drug programs in 30 registered trials: 17 Phase 2, 12 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology, Neurology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Carmustine
Glutathione reductase inhibitor
GSRPhase 1Pancreatic Adenocarcinoma Metastatic; Metastatic Malignant Neoplasm in the Liver; Glioblastoma Multiforme; Non-Hodgkin Lymphoma …Dec 2028
Melphalan
Alkylating agent (nitrogen mustard derivative)
UNKNOWNPhase 1Pancreatic Adenocarcinoma Metastatic; Retinoblastoma; Primary Immunodeficiency (PID); Refractory and/or Relapsed Metastatic Solid Tumors …Dec 2028
Vitamin B12b (Hydroxocobalamin)
Cyanocobalamin precursor; B12 vitamin cofactor supplementation
–Phase 1Pancreatic Adenocarcinoma MetastaticDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01962415MelphalanPhase 2Primary Immunodeficiency (PID)ImmunologyNov 2026
NCT00544466MelphalanPhase 1LeukemiaOncologyDec 2026
NCT01054196MelphalanPhase 1Multiple MyelomaOncologyDec 2026
NCT01804634MelphalanPhase 2Refractory and/or Relapsed Metastatic Solid TumorsOncologyJan 2027
NCT04728633CarmustinePhase 2Metastatic Malignant Neoplasm in the LiverOncologyJan 2027
NCT05052957CarmustinePhase 2Glioblastoma MultiformeOncologyMar 2027
NCT06313502MelphalanPhase 1Plasma Cell DisorderOncologyApr 2027
NCT03118492MelphalanPhase 1Secondary MyelofibrosisOncologyApr 2027
NCT04483206MelphalanPhase 1Multiple MyelomaOncologyJun 2027
NCT01885689MelphalanPhase 2Adult Acute Lymphoblastic Leukemia in RemissionOncologyAug 2027
NCT06028828MelphalanPhase 2Allogeneic Hematopoietic Stem Cell TransplantationOncologySep 2027
NCT03125642MelphalanPhase 2Non-Hodgkin LymphomaOncologySep 2027
NCT03125642CarmustinePhase 2Non-Hodgkin LymphomaOncologySep 2027
NCT02605421MelphalanPhase 2NeuroblastomaOncologyOct 2027
NCT03821610MelphalanPhase 2Acute Lymphoblastic LeukemiaOncologyNov 2027
NCT00871013MelphalanPhase 2MyelomaOncologyDec 2027
NCT04799002MelphalanPhase 3RetinoblastomaOncologyDec 2027
NCT04232085MelphalanPhase 2Primary Immune Deficiency DisorderHematologyDec 2027
NCT05083754CarmustinePhase 1Glioblastoma MultiformeOncologyJan 2028
NCT05504291MelphalanPhase 2Bilateral RetinoblastomaOncologyMar 2028
NCT04150042MelphalanPhase 1Pancreatic Adenocarcinoma MetastaticOncologyDec 2028
NCT04150042CarmustinePhase 1Pancreatic Adenocarcinoma MetastaticOncologyDec 2028
NCT04222062CarmustinePhase 2Brain Tumor - MetastaticOncologyDec 2028
NCT04150042Vitamin B12b (Hydroxocobalamin)Phase 1Pancreatic Adenocarcinoma MetastaticOncologyDec 2028
NCT04150042Vitamin B12b (Hydroxocobalamin)Phase 1Pancreatic Adenocarcinoma MetastaticOncologyDec 2028
NCT07025824MelphalanPhase 2AML - Acute Myeloid LeukemiaHematologySep 2029
NCT00716066CarmustinePhase 2Autoimmune DiseaseNeurologyJan 2030
NCT06626516CarmustinePhase 1Metastatic Uveal MelanomaOncologyOct 2030
NCT07582172MelphalanPhase 2Acute Myeloid Leukemia With Complex KaryotypeOncologyNov 2031
NCT05508009MelphalanPhase 1SIODImmunologyOct 2032

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

UNKNOWN (1) GSR (1)

Companies with the same targets

Gilead Sciences Iterum Therapeutics, International Colgate Palmolive Vaxcyte Zhejiang Raygene Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.